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A novel coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV), has recently been iden-
tified as the causative agent of severe acute respiratory syndrome (SARS). SARS-CoV appears similar to other
coronaviruses in both virion structure and genome organization. It is known for other coronaviruses that the
spike (S) glycoprotein is required for both viral attachment to permissive cells and for fusion of the viral
envelope with the host cell membrane. Here we describe the construction and expression of a soluble codon-
optimized SARS-CoV S glycoprotein comprising the first 1,190 amino acids of the native S glycoprotein (S1190).
The codon-optimized and native S glycoproteins exhibit similar molecular weight as determined by Western
blot analysis, indicating that synthetic S glycoprotein is modified correctly in a mammalian expression system.
S1190 binds to the surface of Vero E6 cells, a cell permissive to infection, as demonstrated by fluorescence-
activated cell sorter analysis, suggesting that S1190 maintains the biologic activity present in native S glycop-
rotein. This interaction is blocked with serum obtained from recovering SARS patients, indicating that the
binding is specific. In an effort to map the ligand-binding domain of the SARS-CoV S glycoprotein, carboxy-
and amino-terminal truncations of the S1190 glycoprotein were constructed. Amino acids 270 to 510 were the
minimal receptor-binding region of the SARS-CoV S glycoprotein as determined by flow cytometry. We
speculate that amino acids 1 to 510 of the SARS-CoV S glycoprotein represent a unique domain containing the
receptor-binding site (amino acids 270 to 510), analogous to the S1 subunit of other coronavirus S
glycoproteins.
Severe acute respiratory syndrome (SARS) is a recently de-
scribed disease that has affected approximately 8,500 people
worldwide with a mortality rate of approximately 10% (accord-
ing to the World Health Organization). The causative agent of
SARS is a newly identified coronavirus, SARS-CoV, first iso-
lated by propagation on Vero E6 cells (5, 12, 17). The SARS-
CoV genome has been sequenced, and the probable coding
regions for viral proteins have been deduced. Like other coro-
naviruses, SARS-CoV is a positive-strand RNA virus that en-
codes four main structural proteins, M, N, E, and S (20).
Genetic analysis of the coding regions has demonstrated that
SARS-CoV is distinct from the three known antigenic groups
of coronaviruses (5, 12); however, recent data studying the
replicase gene suggest that SARS-CoV may be most related to
group 2 coronaviruses (21).
The S glycoprotein, a 1,255-amino-acid type I membrane
glycoprotein (20), is the prominent protein present in the viral
membrane and presents as the typical spike structure found on
all coronaviruses. SARS-CoV S glycoprotein domain structure
has been deduced from sequence analysis (20). The S glyco-
protein consists of a leader (amino acids 1 to 14), an ectodo-
main represented by amino acids 15 to 1190, a membrane-
spanning domain (amino acids 1191 to 1227), and a short
intracellular tail (amino acids 1227 to 1255) (20). The full-
length SARS-CoV S glycoprotein has 23 potential N-linked
glycosylation sites predicted by sequence analysis (20). For
group 2 and group 3 coronaviruses, the S glycoprotein is post-
translationally cleaved into two noncovalently associated sub-
units, S1 and S2 (6, 15, 22, 23). The motif that leads to cleavage
of the subunits in these coronaviruses (15) is not present in
SARS-CoV, suggesting that cleavage of the SARS-CoV S gly-
coprotein does not occur (20).
Although the process by which SARS-CoV penetrates the
cellular membrane has not been determined, the mechanism is
most likely similar to that described for other coronaviruses.
The S glycoprotein interacts with the cellular surface, and for
coronaviruses HCoV-229E and mouse hepatitis virus (MHV)
amino acids 1 to 547 (2) and 1 to 330 (13), respectively, are
required for binding to the cellular receptor. This interaction is
predicted to lead to conformational changes in the carboxy-
terminal half of the S glycoprotein. This change culminates in
fusion of the virus and host cell membranes, allowing for entry
of the virus (25–27). Sequence analysis of the SARS-CoV S
glycoprotein using the LearnCoil VMF software has predicted
the presence of two coiled-coil motifs present at amino acids
900 to 974 and 1148 to 1190. These coiled-coil structures are
present in the fusion domain of many varied viruses, including
MHV (4, 11, 14) and human immunodeficiency virus type 1
(9), of which entry events have been predicted to occur as
described above.
Here we describe the construction and expression of a
codon-optimized gene encoding the soluble ectodomain
(amino acids 1 to 1190) of the SARS-CoV S glycoprotein.
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Codon-optimized S glycoprotein (S1190) was secreted into the
growth medium and purified by affinity chromatography. Ex-
pression levels of secreted S1190 glycoprotein were determined
to be approximately 5 mg/liter after purification. The S1190
synthetic S glycoprotein was shown to have an apparent mo-
lecular mass of 170 kDa, a size similar to that observed for
native S protein expressed in SARS-CoV-infected Vero E6
cells. Purified S1190 protein was readily detected by human
SARS convalescent-phase serum (provided by Larry Ander-
son, Centers for Disease Control and Prevention [CDC]) as
determined by Western blot analysis. Synthetic S glycoprotein
could also bind to the surface of Vero E6 cells, demonstrating
that soluble, codon-optimized S glycoprotein retains the bio-
logic activity present in the native molecule. Carboxy-terminal
truncations of S1190 were produced, and it was demonstrated
that the amino acids 1 to 510 (S510) are required for binding to
Vero E6 cell surfaces. Amino-terminal truncations of the S510
glycoprotein demonstrated that amino acids 270 to 510 contain
the minimal receptor-binding domain of the SARS-CoV S
glycoprotein.
MATERIALS AND METHODS
Construction of a synthetic gene encoding soluble codon-optimized SARS-CoV
spike (S) protein and S protein fragments. The amino acid sequence of the
SARS-CoV (Urbani strain) S protein was obtained from the NCBI database
(AAP13441). The soluble portion of the protein was determined to be the first
1,190 amino acids (of 1,255) and, as such, only the DNA encoding this sequence
was synthesized. The DNA sequence was codon optimized for mammalian cell
expression (1, 16), replacing the natural codons with the following optimum
codons: alanine (GCC), arginine (CGC), asparagine (AAC), aspartic acid
(GAC), cysteine (TGC), glutamic acid (GAG), glutamine (CAG), glycine
(GGC), histidine (CAC), isoleucine (ATC), leucine (CTG), lysine (AAG), me-
thionine (ATG), phenylalanine (TTC), proline (CCC), serine (TCC), threonine
(ACC), tryptophan (TGG), tyrosine (TAC), and valine (GTG). Runs of Cs and
Gs were avoided, to simplify both synthesis of oligonucleotides as well as PCR
conditions. When these stretches of Gs and Cs occurred, suboptimal codons were
used. The 5 end of the gene was modified to include a restriction site for HindIII
and an irrelevant upstream overhang to facilitate cloning. The 3 end of the
synthetic gene was similarly modified to include an XbaI site and overhang
sequences.
A total of 104 oligonucleotides were obtained (Integrated DNA Technologies;
polyacrylamide gel electrophoresis purified) that represented the entire coding
region of both the sense and antisense strands of the S protein gene, as well as
engineered restriction sites. The most-5 oligonucleotide of each strand was a
35-mer and all others were 70-mers, resulting in a 35-bp overlap between strands.
In essence, the oligonucleotides from the sense strand fully overlapped the
oligonucleotides of the antisense strand, leaving no gaps. Construction of the
codon-optimized gene was performed as follows. Thirteen groups of oligonucle-
otides were selected that contained eight oligonucleotides (four sense and four
antisense) in each group. PCR was performed on each set in a reaction mixture
containing 20 M deoxynucleoside triphosphates, 30 pmol of end oligonucleo-
tides, 10 pmol of internal oligonucleotides, 1 cloned Pfu reaction buffer (Strat-
agene), and 1 U of Turbo Pfu (Stratagene). Thirty cycles of thermocycling (95°C
for 15 s, 62°C for 30 s, and 68°C for 2 min) were performed, and the PCR
products were resolved on 1% agarose gels. Specific products were gel purified
(Qiagen) and divided into four separate groups containing either three or four of
the first-step PCR products. PCR was again performed on each group, using
oligonucleotides corresponding to the most-5 end of each strand. These four
PCR products were resolved on 0.8% agarose gels and gel purified as before. The
four PCR products were mixed and amplified using oligonucleotides correspond-
ing to the 5 end of each strand of the entire synthetic gene. This final amplifi-
cation yielded the 3,605-bp sequence consisting of the synthetic gene flanked by
restriction sites.
The final PCR product encoding the SARS-CoV S glycoprotein gene was
digested with HindIII and XbaI and cloned into pcDNA3.1 Myc/His (Invitrogen)
in frame with the c-myc and His6 epitope tags. The cloned gene was sequenced
to confirm that no errors had been accumulated during the PCR process. Of the
four clones sequenced, none had sequence errors and no further genetic manip-
ulations were required.
Once the sequence of the full-length soluble SARS-CoV S glycoprotein gene
was confirmed, DNA encoding carboxy-terminally truncated soluble S glycopro-
teins was synthesized by PCR amplifying the desired fragment from the vector
containing the full-length, codon-optimized gene encoding the S glycoprotein.
Since the codon-optimized S1190 gene was used as a template for PCR, all
truncated constructs were also codon optimized. Truncations were then cloned
into pcDNA3.1 Myc/His as described above, and the DNA sequence was con-
firmed.
FIG. 1. Expression and purification of soluble S1190 glycoprotein.
Codon-optimized S1190 glycoprotein was cloned into pcDNA3.1 Myc/
His and expressed in HEK-293T/17 cells to a level of 5 mg/liter.
Protein was purified using metal-affinity chromatography, dialyzed,
and concentrated. Purified protein was analyzed by Coomassie staining
(A) or Western blotting using the anti-c-myc antibody for detection
(B).
FIG. 2. The apparent molecular mass of the S1190 protein is similar
to that of native S protein. S1190 protein (200 ng), Vero E6 cell extract,
and SARS CoV-infected Vero E6 cell extract were resolved by SDS-
PAGE. Proteins were transferred to a solid support, and Western
blotting was performed using either human SARS convalescent-phase
serum (top panel) or mouse anti-synthetic S protein (bottom panel).
The major species detected for S1190 and SARS-infected extract in
both cases was of an apparent molecular mass of approximately 170
kDa. No signal was observed in the lane containing the Vero E6 cell
extract.
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N-terminal truncations were also synthesized. PCR was used to amplify the
leader sequence of the S1190 gene, containing a 3 overhang corresponding to
downstream sequences. The downstream sequences were then amplified and
combined with the leader-overhang PCR product. PCR was again performed to
synthesize copies of a gene that consisted of the S1190 leader fused immediately
5 of the downstream coding region. These constructs essentially created dele-
tions between the leader peptide and the desired downstream sequence.
Cells and cell culture. HEK-293T/17 and Vero E6 cells, obtained from the
American Type Culture Collection, were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum and 100 IU of
penicillin-streptomycin (complete DMEM) at 37°C with 5% CO2. To harvest
cells, phosphate-buffered saline (PBS) containing 5 mM EDTA was added to the
tissue culture dish and incubated for 5 min at room temperature.
Expression and purification of codon-optimized S glycoproteins. All con-
structs were transfected into HEK-293T/17 cells using Lipofectamine 2000 (In-
vitrogen) as described by the manufacturer. Briefly, cells were grown to 80%
confluence in 150-mm tissue culture dishes in 15 ml of DMEM–10% fetal calf
serum (FCS). Thirty micrograms of DNA mixed with 75 l of Lipofectamine
2000 was added to the cells, and plates were incubated overnight at 37°C.
Medium was removed and stored, and fresh complete DMEM was added to the
cells. Cells were incubated for an additional 24 h, at which time 3 mM sodium
butyrate (Sigma) was added to the medium. An additional 24-h incubation was
performed, and supernatants were removed from the plate. This supernatant was
combined with the transfection supernatant and filtered using a 0.45-mm-pore-
size filter apparatus. Filtered supernatants were mixed with Ni-nitrilotriacetic
acid–agarose (Invitrogen) at a ratio of 0.5 ml of agarose for 40 ml of culture
supernatant. Supernatant-agarose mixtures were incubated for 2 h on a rocking
platform at room temperature. Agarose was removed from the supernatant by
column filtration. Beads were washed with PBS, and protein was eluted using 250
mM imidazole. Eluted protein was dialyzed against PBS for 2 h at room tem-
perature and concentrated to 2 ml with an Amicon Centriprep YM-10. Sodium
dodecyl sulfate-PAGE (SDS-PAGE) and Coomassie blue staining were used to
determine purity of isolated proteins.
SDS-PAGE and Western blotting. Various concentrations of purified S glyco-
proteins were mixed with 2 reducing Laemmli sample buffer and boiled for 5
min. Samples were resolved using 12% Novex gels (Invitrogen) for 1.5 h at 200
V. Gels were transferred to Immobilon P (Millipore) as described by the man-
ufacturer, and Western blot analysis was performed. Proteins were detected
using the anti-c-myc (9E10) antibody (0.1 g/ml; Sigma), followed by an anti-
mouse immunoglobulin G (IgG)-horseradish peroxidase conjugate (1:5,000;
Jackson ImmunoResearch). For detection with human convalescent-phase se-
rum (provided by Larry Anderson, CDC), a dilution of 1:2,000 was used followed
by detection with anti-human IgG–horseradish peroxidase (Jackson ImmunoRe-
search). For detection with mouse serum raised against synthetic S glycoproteins,
the method was as described for the anti-c-myc antibody. Membranes were
incubated with enhanced chemiluminescence reagent for 1 min and exposed to
X-Omat-AR film for various periods of time.
S glycoprotein-binding assay. Vero E6 or HEK-293T/17 cells were harvested
with PBS–5 mM EDTA and aliquoted to microcentrifuge tubes (1  106 to 5 
106 each). Pellets were resuspended in PBS containing 10% fetal bovine serum
and various concentrations of the truncated soluble S glycoproteins (0.01 nM to
1 M). Cells and S glycoprotein were incubated for 1 h at room temperature and
washed once in PBS–2% FCS. Pellets were resuspended in 100 l of PBS–2%
FCS containing 10 g of anti-c-myc (9E10) antibody/ml, incubated for 1 h at 4C,
and washed once in PBS–2% FCS. Pellets were resuspended in 100 l of
PBS–2% FCS containing 5 l of anti-mouse IgG–phycoerythrin (PE; Jackson
ImmunoResearch). Mixtures were incubated at 4°C for 40 min and washed twice,
and fluorescence-activated cell sorter (FACS) analysis was performed using a
FACScan instrument with CellQuest software (Becton Dickinson).
In order to specifically block S glycoprotein binding to Vero E6 cells, human
convalescent-phase serum was incubated with cells and S glycoprotein. Serum
concentration never exceeded 10%, and as human serum was diluted, FCS was
used to normalize all reaction mixtures to a final concentration of 10% serum.
Normal human serum was used as a negative control.
RESULTS
Construction and expression of soluble codon-optimized
SARS-CoV S glycoprotein. The genes that encode viral pro-
teins quite often have poor codon usage, leading to difficulties
in producing sufficient quantities of purified recombinant pro-
tein (8). To overcome the possible issue of poor codon usage of
the S glycoprotein gene, we constructed a synthetic codon-
optimized S glycoprotein gene. Analysis of optimal codon us-
age in mammalian cells has been described elsewhere (1, 16).
A codon-optimized gene encoding the first 1,190 amino acids
of the SARS-CoV S glycoprotein (S1190) was synthesized and
cloned into the mammalian expression vector pcDNA 3.1 Myc/
His. The first 1,190 amino acids represent the predicted leader
sequence and extracellular domain of the S glycoprotein, ex-
cluding transmembrane and intracellular domains. As such,
when expressed, the gene product is a secreted, soluble version
of the S glycoprotein. The vector used contains two epitope
tags, the c-myc and His6 tags. The c-myc tag was exploited for
FIG. 3. S1190 specifically binds to the surface of Vero E6 cells.
(A) Vero E6 cells (diamonds) or HEK-293T/17 cells (squares) were
incubated with 1 to 100 nM S1190 protein to determine the ability to
bind to cell surfaces. S1190 binding was detected by anti-c-myc antibody
followed by anti-mouse IgG–PE. Samples were analyzed by flow cy-
tometry, and mean fluorescence intensity was plotted. (B) Vero E6
cells were incubated with 30 nM S1190 glycoprotein in the presence of
increasing concentrations of normal (circles) or SARS convalescent-
phase (squares) human serum. Serum concentration was maintained at
10% by the addition of fetal bovine serum. Binding was measured by
flow cytometry, and the results were plotted as a percentage of the
signal observed in a sample containing no test serum.
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immunoprecipitations and Western blot analysis of proteins,
while the His6 tag allowed for native purification of expressed
protein.
pcDNA 3.1 Myc/His S1190 was transfected into HEK-
293T/17 cells, supernatants were recovered, and S1190 glyco-
protein was purified by metal-affinity chromatography. Pro-
teins were eluted from the resin with imidazole, dialyzed, and
concentrated. S1190 concentration was determined by both
spectrophotometry and bicinchoninic acid, both of which
yielded equivalent results (data not shown). It was determined
that secreted S1190 was expressed at a level of approximately 5
mg/liter after purification.
To assess purity of the S1190 glycoprotein preparations, pro-
teins were resolved by SDS-PAGE and visualized by Coomas-
sie staining (Fig. 1A). The major band of a relative molecular
mass of 170 kDa was observed, and purity of this protein was
estimated to be greater than 90%. To ensure that the purified
protein was S1190, proteins were resolved using SDS-PAGE
and protein identity was determined using Western blot anal-
ysis utilizing the anti-c-myc antibody, 9E10. As shown in Fig.
1B, a major band of approximately 170 kDa was observed. The
distribution of this band in the gel matrix as well as the larger-
than-expected apparent molecular weight suggested that this
protein is glycosylated, as expected. The lower-molecular-
weight species detected in Fig. 1B are clearly carboxy-terminal
fragments of the S1190 protein, as demonstrated by detection
with the carboxy-terminal myc tag. It is unclear whether these
products represent natural cleavage products or are a conse-
quence of overexpression and purification of the S1190 glyco-
protein. In any case, these species represent a very small frac-
tion of the total purified protein.
To determine if HEK-293T/17 cells appropriately posttrans-
lationally modify the synthetic S glycoprotein, we attempted to
compare the relative molecular weight of the codon-optimized
S1190 protein with that observed for native S protein. SARS-
CoV-infected Vero cell lysate was obtained from the CDC.
Lysate, equivalent to 2  104 solubilized infected cells along
with 200 ng of codon-optimized S glycoprotein, was resolved
using SDS-PAGE. Gels were transferred to solid support, and
Western blotting was performed using human SARS patient
convalescent-phase serum as a detection reagent. As shown in
Fig. 2 (top panel), the main species detected in the SARS-
infected Vero E6 cells and S1190 lanes had an apparent molec-
ular mass of approximately 170 kDa. No bands were detected
in the uninfected Vero E6 lysate control. Lower-molecular-
weight species were again detected in the lane containing S1190
glycoprotein. These bands were not observed in the lane con-
taining native SARS-CoV S glycoprotein. As demonstrated in
Fig. 1B, this discrepancy in banding pattern between the two
lanes was most likely a function of the amount of protein
present in the lane. When smaller quantities of synthetic S1190
glycoprotein were resolved by SDS-PAGE, we only observed
the main 170-kDa species. It remains possible, however, that
these smaller fragments represent an artifact of overexpression
in the HEK-293T/17 cells.
To ensure that the proteins observed were in fact the S
glycoproteins, we performed Western blot analysis, this time
using mouse serum raised against the synthetic S glycoprotein.
As shown in Fig. 2 (bottom panel), a major species of approx-
imately 170 kDa was observed in both the S1190 and infected
Vero E6 cell lysate lanes. The expected contribution of the
transmembrane domain and cytoplasmic tail to the molecular
weight of the native S protein is expected to be negligible.
FIG. 4. Soluble S glycoproteins. Shown is a schematic of the native SARS CoV S glycoprotein as well as the various S glycoproteins synthesized.
Landmarks include the leader peptide (black; amino acids 1 to 14), the predicted ectodomain (white; amino acids 15 to 1190), the transmembrane
domain (dark gray; amino acids 1191 to 1227), and the cytoplasmic tail (light gray; amino acids 1228 to 1255). All soluble constructs were
C-terminally truncated, and the relative sizes are shown.
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These data suggest that codon-optimized S glycoprotein is
modified similarly to native S glycoprotein.
Codon-optimized SARS-CoV S glycoprotein binds to Vero
E6 cells. In order for virus to infect target cells, it must first
bind to the viral receptor on the cell surface. The protein that
mediates this binding is predicted to be the S glycoprotein.
Unfortunately, at this time, the cellular receptor for the viral S
glycoprotein is not known. However, Vero E6 cells are readily
infectible with SARS-CoV in culture and are assumed to ex-
press the receptor for the SARS-CoV S glycoprotein.
A FACS-based assay was developed to measure the ability of
codon-optimized soluble S glycoprotein to bind to the Vero E6
cell surface. Briefly, Vero E6 cells were incubated with various
concentrations of soluble S1190 glycoprotein to allow for bind-
ing. In order to detect S1190 binding to the cell surface, we took
advantage of the fact that the soluble S1190 protein is fused to
the c-myc epitope tag. S glycoprotein-bound cells were incu-
bated with the anti-c-myc antibody 9E10, and bound anti-c-myc
antibody was detected using an anti-mouse–PE–conjugated an-
tibody. Cells were subsequently analyzed by flow cytometry,
and the results are shown in Fig. 3A. Soluble synthetic S1190
glycoprotein readily bound to the surface of Vero E6 cells in a
dose-dependent manner. Uniform binding was observed for
the entire population of Vero E6 cells and not a minor subset
(data not shown). To demonstrate specificity of the interaction
of S1190 with a possible viral receptor expressed on the surface
of Vero E6 cells, we performed the S1190-binding assay using
HEK-293T/17 cells. This cell type is not expected to express
the SARS CoV receptor, as demonstrated by the inability of
this cell to be infected with SARS-CoV in vitro (data not
shown). S1190 binding to HEK-293T/17 cell surfaces was not
observed at any of the concentrations tested (Fig. 3A). These
data demonstrate that soluble synthetic S1190 glycoprotein pos-
sesses biological properties expected to be present in the native
S glycoprotein.
To ensure that the binding observed was in fact specific, we
attempted to block binding using antibodies specific to the
native SARS-CoV S glycoprotein. We obtained a pool of se-
rum from individuals previously infected with SARS-CoV from
the CDC. The antibodies present in this serum would be an-
ticipated to disrupt the binding of S glycoprotein to the cellular
receptor of the virus. Vero E6 cells were incubated with 30 nM
S1190 glycoprotein in the presence of various concentrations of
convalescent-phase or normal human serum. S glycoprotein
binding was detected using FACS analysis as described above
(Fig. 3B). Convalescent-phase serum specifically blocked bind-
ing of synthetic S1190 glycoprotein to the surface of Vero E6
cells. In contrast, serum from uninfected individuals had no
effect on S1190 binding. Unfortunately, the control serum and
convalescent-phase serum were not matched, i.e., serum from
the same individual pre- and postexposure. To confirm the
result above in a more controlled manner, rabbit serum was
also raised against the S1190 glycoprotein. This serum could
block the interaction of S1190 glycoprotein with Vero E6 cell
surfaces, whereas preimmune rabbit serum could not (data not
shown). These data demonstrate that S1190 binding to the sur-
face of Vero E6 cells is indeed specific.
Localization of the SARS-CoV S glycoprotein ligand-bind-
ing domain to amino acids 1 to 510. It is known for other
coronaviruses that the amino-terminal half of the S glycopro-
tein spike contains the sequences responsible for ligand bind-
ing. To further characterize the interaction between SARS-
CoV S glycoprotein and the Vero E6 cell surface, we created
C-terminal truncations of the soluble S1190 glycoprotein. DNA
encoding these truncations was synthesized via PCR using
S1190 DNA as template. All truncated genes retained the c-myc
and His6 tags to simplify detection and purification. Specifi-
cally, DNA encoding S350, S490, S590, S690, and S790 was cloned
into the mammalian expression vector pcDNA3.1 Myc/His.
The constructs, when expressed, contained amino acids 1
through 350, 490, 590, 690, and 790, respectively (Fig. 4). The
constructs were transfected into HEK-293T/17 cells as de-
scribed above, and secreted proteins were purified by metal-
affinity chromatography (Fig. 5A). As previously found, all
proteins were expressed at levels of 5 mg/liter and appeared
to be glycosylated. Purified glycoproteins were incubated with
FIG. 5. Expression and binding of C-terminally truncated S pro-
teins. (A) DNA encoding C-terminally truncated S proteins (S350, S490,
S590, S690, and S790) was synthesized via PCR using the vector encoding
the S1190 glycoprotein as template. PCR products were cloned into
pcDNA3.1 Myc/His and expressed in 293T cells. Western blotting was
performed using the anti-c-myc antibody for detection. (B) Vero E6
(black bars) or HEK-293T/17 (gray bars) cells were incubated with a
100 nM concentration of each soluble S glycoprotein fragment and
detected with antibody directed against the c-myc tag. FACS analysis
was performed, and mean fluorescence intensity was plotted.
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either Vero E6 cells or HEK-293T/17 cells with various con-
centrations of the S glycoprotein fragments, and FACS analysis
was performed. Figure 5B shows the results of each protein at
a concentration of 100 nM. S proteins containing at least the
first 590 amino acids specifically bound to the surface of Vero
E6 cells but not to HEK-293T/17 cells. Binding of S350 and S490
to the cell surface was essentially equivalent for both HEK-
293T/17 and Vero E6 cells. This indicates that these regions of
the S glycoprotein do not specifically bind to the cell surface.
Even at the highest concentrations tested (1 M), no specific
binding was observed for proteins S350 and S490 (data not
shown). These data suggest that the first 590 amino acids of the
SARS-CoV S protein are required for interaction with the
surface of Vero E6 cells.
To more finely map the critical ligand-binding domain of the
SARS-CoV S glycoprotein, we created more soluble constructs
covering the sequence between S490 and S590. Specifically, we
synthesized DNA that encoded S500, S510, S520, S540, S550, S560,
S570, and S580 (nomenclature as described above). S530 was not
cloned, since no positive colonies were obtained on the initial
screen. The constructs were expressed in HEK-293T/17 cells,
and the proteins were purified (Fig. 6A) as described above. A
100 nM concentration of each truncated protein was incubated
with Vero E6 cells to determine cell surface interaction. Bind-
ing was detected using the anti-c-myc antibody followed by an
anti-mouse–PE antibody. Flow cytometry was performed, and
the results are shown in Fig. 6B. All proteins containing at least
the first 510 amino acids could specifically bind to the surface
of Vero E6 cells. Constructs smaller than S510 gave signals
equivalent to that seen with secondary antibody alone. Inter-
action of S glycoprotein fragments with Vero E6 cells was
specific, as demonstrated by blocking with convalescent-phase
serum (data not shown). These data demonstrate that the first
510 amino acids of the SARS-CoV S protein are both neces-
sary and sufficient for interaction with receptor expressed by
Vero E6 cells. The first 510 10 amino acids represent a domain
analogous to the S1 domain of other coronavirus S glycoproteins.
S510 and S1190 have similar affinities for Vero E6 cells. To
ensure that the amino-terminal 510-amino-acid domain repre-
sents the entire receptor-binding domain, we attempted to
approximately measure the binding kinetics of both S1190 and
S510 for Vero E6 cells. S1190 and S510 were incubated with Vero
E6 cells at concentrations ranging from 0.01 to 1 M. As a
negative control, S350 was included in the experiment. S glyco-
protein binding was detected via flow cytometry as described
before (Fig. 7). Although FACS analysis cannot be used to
FIG. 6. Amino acids 1 to 510 represent the ligand-binding domain of the SARS CoV S protein. Constructs encoding C-terminally truncated
proteins covering the gap between amino acids 490 and 590 (S510, S520, S540, S550, S560, S570, and S580) were synthesized using PCR and cloned into
pcDNA3.1 Myc/His. All constructs were expressed in HEK-293T/17 cells and purified by metal-affinity chromatography. (A) Proteins were resolved
by SDS-PAGE and Western blot analysis performed in conjunction with detection with the anti-c-myc antibody. (B) All purified S glycoproteins
were incubated with Vero E6 cells at a concentration of 100 nM. Binding was measured using the anti-c-myc antibody and FACS analysis. Mean
fluorescence intensity was plotted for each construct and compared.
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measure the true affinity of protein-protein interactions, it can
be used to compare relative affinity of two differing proteins.
S1190 and S510 exhibited very similar profiles for binding to the
Vero E6 cell surface. These data suggest that S510 binds to
Vero E6 cells at least as well as S1190 binds. S350 did not bind
specifically to the surface of Vero E6 cells at any concentration
tested. All other soluble S glycoproteins containing at least the
first 510 amino acids were also tested in this way, and all
showed similar binding profiles to the cellular surface (data not
shown). These data demonstrate that S510 is indeed the ligand-
binding domain of the SARS CoV S protein.
Amino acids 270 to 510 comprise the minimal ligand-bind-
ing domain of the soluble S glycoprotein. Amino-terminal
truncations of the S510 glycoprotein were synthesized to map
the minimal receptor-binding region within the S1 domain of
the spike glycoprotein. Specifically, sequences corresponding
to the leader peptide were fused to sequences downstream in
the S510 coding region, resulting in genes encoding S90-510
(amino acids 90 to 510), S150-510 (amino acids 150 to 510),
S210-510 (amino acids 210 to 510), S270-510 (amino acids 270 to
510) (Fig. 8A), S330-510 (amino acids 330 to 510), and S390-510
(amino acids 390 to 510). All constructs were transfected into
HEK-293T/17 cells, and the protein was purified by metal-
affinity chromatography. Interestingly, only expression of S270-510
was observed, and expression levels were similar to the other S
glycoprotein fragments (data not shown). Purified S270-510 was
incubated with Vero E6 cells at various concentrations, FACS
analysis was performed, and the results are shown in Fig. 8B.
S270-510 binding to Vero E6 cells was nearly identical to that
observed for S590. S350 showed no specific binding to Vero E6
cells. Both S270-510 and S590 did not demonstrate specific bind-
ing to the surface of HEK-293T/17 cells. These data demon-
strate that amino acids 270 to 510 contain the minimal domain
required for interaction with the surface of Vero E6 cells.
DISCUSSION
Understanding the biochemistry by which SARS-CoV in-
fects target cells is of paramount importance in preventing
infection and death associated with SARS. The S glycoprotein,
which mediates viral entry, is an obvious protein for study to
approach inhibiting viral infection. Here we describe the syn-
thesis and expression of codon-optimized SARS-CoV S glyco-
protein. Codon optimization has many benefits over traditional
cloning techniques, the most obvious of which is the yield of
protein obtained. We have expressed the full-length ectodo-
main of the S glycoprotein (S1190) at a level of approximately
5 mg/liter. This yield is greater than typically seen for native
viral glycoproteins expressed in mammalian cells (8). We have
not formally compared the two expression systems, but it is our
experience that codon optimizing of viral glycoprotein genes
for mammalian cells greatly increases expression levels. At this
time, we have the ability to purify 10 mg of S1190 protein at
one time, allowing for diverse studies to be undertaken.
Comparisons between S1190 glycoprotein and native SARS-
CoV S glycoprotein were performed. The relative molecular
weight of the S1190 glycoprotein was essentially identical to that
of native S glycoprotein as determined by SDS-PAGE and
Western blotting. S1190 protein did, however, demonstrate pro-
teolytic breakdown products not observed in the native protein
(Fig. 2). One explanation for this difference is the amount of
protein tested in the assay. Significantly more S1190 protein was
resolved on the gel than the native S glycoprotein-containing
viral lysate. It is possible that these smaller S glycoprotein
fragments are present in virally infected cells, but this Western
blotting is not sensitive enough to detect them. When quanti-
ties of S1190 glycoprotein comparable to that of native glyco-
protein in the viral lysate were resolved by SDS-PAGE, we did
not see the smaller S glycoprotein fragments (Fig. 1). It is also
possible that overexpression of S glycoprotein in mammalian
cells leads to degradation of a portion of the expressed S
glycoprotein. In any case, the majority of the codon-optimized
S1190 has an apparent molecular weight that is equivalent to
that of native S glycoprotein.
It has been shown that SARS-CoV can readily infect Vero
E6 cells in culture (5, 12, 17). The receptor for the SARS-CoV
S glycoprotein has not been identified, but one can assume that
it is expressed on the surface of Vero E6 cells. S1190 protein
bound to the surface of Vero E6 cells in a dose-dependent
manner, and specific antibodies blocked this interaction. These
data suggest that soluble S1190 glycoprotein possesses some of
the biologic activities present in the native S glycoprotein,
specifically receptor binding.
The S glycoprotein of transmissible gastroenteritis virus has
been shown to interact not only with the receptor to mediate
viral entry but also with sialic acid (18). The latter interaction
is not required for fusion but may aid in enteropathogenesis
(10). It is a formal possibility that the interaction of soluble
SARS-CoV S1190 glycoprotein with Vero E6 cell surfaces is
mediated not solely by receptor, but in combination with car-
bohydrate residues on the Vero E6 cell surface. The interac-
tion of S1190 with ligands other than the cellular receptor could
complicate the analysis of S1190 binding to Vero E6 cell sur-
faces. Identification of the SARS-CoV cellular receptor will
allow us to clarify this issue. In any case, the binding of S1190 is
specific to the permissive Vero E6 cells.
We have determined that the first 510 amino acids of the
SARS CoV S glycoprotein contain the entire ligand-binding
domain. Domain structures of the SARS-CoV S protein can
FIG. 7. S510 and S1190 have comparable binding profiles for Vero
E6 cell surfaces. Vero E6 cells were incubated with various concen-
trations of S1190 (squares), S510 (triangles), and S350 (circles) glycopro-
teins. Binding was detected with the anti-c-myc antibody, and FACS
analysis was performed. Concentration versus mean fluorescence in-
tensity was plotted, and the results for each protein were compared.
4558 BABCOCK ET AL. J. VIROL.
 at UNIV O
F M
ASS M
ED SCH on August 4, 2008 
jvi.asm.org
D
ow
nloaded from
 
now be deduced. For many coronaviruses, such as MHV, the S
protein is cleaved into the ligand-binding subunit (S1) and the
membrane fusion subunit (S2) (6, 15, 22, 23). The receptor-
binding domain of the MHV spike protein has been mapped to
amino acids 1 to 330 (13). These amino acids are contained
within the S1 region. The ligand-binding domain of a corona-
virus that does not express a cleaved S glycoprotein, HCoV-
229E, has also been mapped. The first 547 amino acids of the
HCoV-229E S protein are required for binding to the receptor
hAPN (2). For this viral S glycoprotein, the first 547 amino
acids were termed the S1 domain, the designation based on
ligand-binding capability and not evidence of physically distinct
subunits. Sequence analysis (20) as well as data described
herein (Fig. 2) suggest that, analogous to HCoV-229E, SARS-
CoV S glycoprotein is not cleaved into S1 and S2 subunits.
Interestingly, a domain nearly identical in size to the HCoV-
229E S1 domain contains the ligand-binding domain of SARS-
CoV S glycoprotein. Since the first 510 amino acids of SARS-
CoV S glycoprotein encompass the entire receptor-binding
domain, we propose that amino acids 1 to 510 be termed S1
and amino acids 511 to 1190 be called S2.
N-terminal truncation of the S510 glycoprotein demonstrated
that amino acids 270 to 510 represent the minimal receptor-
binding domain. S270-510 was the only amino-terminal trunca-
tion of the S1 domain that could be expressed in HEK-293T/17
cells. S90-510, S150-510, S210-510, S330-510, and S390-510 expression
levels were below our detection limits. It is unclear why these
truncated constructs were not expressed. The most likely ex-
planation is that sequences were not present in these glyco-
proteins to ensure proper folding. This misfolding may have
prevented secretion into the medium or resulted in degrada-
tion of the various proteins. It is possible that a smaller domain
FIG. 8. S270-510 binds to Vero E6 cells. (A) Schematic representation of the S510 and S270-510 glycoproteins. The black box (amino acids 1 to 14)
represents the S glycoprotein leader sequence. (B) Vero E6 cells or HEK-293T/17 cells were incubated with S350, S590, or S270-510 at concentrations
ranging from 0.1 nM to 1 M. Binding of S glycoproteins was detected using the anti-c-myc antibody followed by anti-mouse IgG conjugated to
PE. FACS analysis was performed, and mean fluorescence was plotted as a function of S glycoprotein concentration.
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than amino acids 270 to 510 confers the ligand binding capacity
of the S glycoprotein, but we believe this is unlikely due to
our inability to express smaller fragments. We speculate that
S270-510 was expressed and secreted, since it represents an
intact receptor-binding domain that possesses the appropriate
sequences required for proper protein folding.
Expression and purification of large quantities of S1190, S510,
and S270-510 glycoproteins will be important for identifying the
SARS-CoV cellular receptor and for crystallization studies of
the SARS-CoV S glycoprotein. S1190 crystallization would give
a better understanding of the mechanism by which the S gly-
coprotein binds to and fuses with susceptible cells. Also, the
S510 and S270-510 glycoproteins present the opportunity to de-
termine the exact structure of the ligand-binding site of the S
glycoprotein.
Finally, for other coronaviruses, such as transmissible gas-
troenteritis virus, MHV, and HCoV-229E, neutralizing epi-
topes are typically present in the S glycoprotein (2, 3, 7, 19, 24).
Neutralizing antibodies directed against the S glycoprotein are
reactive to either the S1 receptor-binding domain or hydro-
phobic residues located in the S2 region. The antibodies spe-
cific for S2 are predicted to interfere with fusion of the viral
and host cell envelopes. We suggest that these codon-opti-
mized S glycoprotein domains are appropriate targets for
monoclonal antibody development or as vaccine candidates.
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